查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1470588

皮肤癌诊断与治疗药物市场：依疾病类型和类型划分－2024-2030年全球预测

Skin Cancer Diagnostics & Therapeutics Market by Disease Type (Melanoma, Non-melanoma), Type (Diagnosis, Therapeutics) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年皮肤癌诊断与治疗药物市场规模为75.4亿美元，2024年达83.1亿美元，2030年达151.1亿美元，预计复合年增长率为10.43%。

皮肤癌诊断包括早期发现皮肤癌的各种程序和技术。诊断过程通常从皮肤检查开始，以识别可疑病变或痣。被诊断出患有皮肤癌后，我们进入治疗阶段。治疗方法取决于癌症的类型和阶段，可能包括切除、莫氏手术或冷冻手术等外科手术。还有非手术治疗方法，如放射线治疗、化疗、免疫治疗、动态治疗等，可单独使用或与手术治疗合併使用。全球皮肤癌发病率上升、医疗保健投资和基础设施增加以及政府和非营利组织提高意识提升计划正在推动对皮肤癌诊断和治疗的需求。将个人化医疗和基因组学引入治疗方案也是一个强大的推动力。然而，与先进诊断和治疗相关的高成本、与治疗相关的潜在副作用和併发症以及获得医疗保健服务的差异可能会阻碍成长。此外，与皮肤癌诊断和治疗相关的程序和技术困难以及熟练人力资源的缺乏也是主要挑战。然而，主要参与者正在探索新的创新领域，包括改进精准医疗技术、开发毒性较小、更有效的药物配方，以及探索免疫疗法和生技药品等新兴领域的潜力，我们的目标是简化和简化护肤诊断和治疗。

主要市场统计
基准年[2023] 75.4亿美元
预测年份 [2024] 83.1亿美元
预测年份 [2030] 151.1亿美元
复合年增长率（%） 10.43%

疾病类型 对黑色素瘤快速、早期诊断和治疗的需求不断增加

黑色素瘤是一种严重的皮肤癌，发生在产生黑色素的细胞中，黑色素是赋予皮肤颜色的色素。诊断需要皮肤镜检查、皮肤切片检查、淋巴结定位和影像检查等方法，治疗包括手术切除、化疗、标靶治疗和免疫治疗。这些选项的优先顺序取决于肿瘤特征、分期和患者健康状况。与非黑色素瘤皮肤癌相比，黑色素瘤转移的机会更高，因此需要更积极的治疗和持续监测。随着疾病的进展，预后通常会恶化。因此，强调早期、准确的诊断。非黑色素瘤皮肤癌主要包括基底细胞癌（BCC）和鳞状细胞癌（SCC），它们的侵袭性通常低于黑色素瘤。虽然这些癌症更常见，但转移的风险要低得多，治疗通常包括手术切除、冷冻手术和早期局部药物治疗。也可以使用动态疗法或放射线治疗。非黑色素瘤的治疗和诊断通常比黑色素瘤的治疗便宜且复杂。

随着皮肤癌患者数量的增加，皮肤癌的治疗方法正在不断改善。

诊断在皮肤癌的治疗中起着至关重要的作用，可以实现早期发现并增加成功治疗的可能性。诊断领域包括各种技术和方法，例如皮肤镜检查、切片检查、影像检查和分子诊断。儘管血液检查不常用于诊断皮肤癌，但它们可以提供有关患者整体健康状况和器官功能的宝贵信息，特别是在癌症可能已经扩散的晚期病例中。皮肤镜检查是一种用于检查皮肤病变的非侵入性诊断工具。超音波、X 光、电脑断层扫描 (CT)、正子断层扫描 (PET) 和磁振造影(MRI) 等影像检查可以帮助检测皮肤癌是否扩散到身体其他部位。如果怀疑皮肤癌已经扩散，可以进行淋巴结切片检查以评估癌细胞是否已扩散到淋巴系统。皮肤切片检查是诊断皮肤癌的主要方法。取出可疑的皮肤组织并在显微镜下检查以检查是否有癌细胞。皮肤癌的治疗方法包括手术到先进的全身疗法和免疫疗法，治疗方法的选择通常取决于皮肤癌的阶段和类型。化疗是针对各阶段的皮肤癌的有效全身性治疗方法，尤其是转移性或进行性。这种治疗方法使用口服或静脉注射的抗癌药物来破坏快速分裂的癌细胞。非侵入性治疗方法越来越受到关注，因为它们透过靶向癌细胞而对周围健康组织的损害最小，从而提供显着的益处。这些治疗方法包括局部治疗、放射线治疗和动态治疗。外科手术的范围从果冻技术（例如冷冻并破坏异常组织）到更广泛的手术（例如莫氏手术），逐层去除癌组织，同时保留尽可能多的健康组织。

区域洞察

美洲，特别是美国和加拿大，拥有先进的医疗保健系统，在皮肤癌研究和诊断方面投入大量资金。患者行为是由高度认识和获得先进治疗的机会所驱动的。公共和私人组织正在提供财务支持和倡议，以降低皮肤癌的发病率和死亡率。该领域的专利数量很高，代表了诊断工具（如痣绘图技术、人工智慧影像分析）以及治疗方法（如标靶治疗和免疫疗法）的重要创新。在欧盟（EU），成员国之间皮肤癌的盛行率和医疗保健的取得情况存在很大差异。儘管对皮肤癌研究和医疗基础设施的投资各不相同，但人们正在透过欧盟的地平线 2020 计画等倡议共同努力协调和推进对抗皮肤癌的斗争。在亚太地区，政府对改善医疗基础设施的支持力道不断加大，保险普及不断提高，导致皮肤癌治疗的需求不断增加。日本和澳洲等拥有先进医疗保健系统的国家在患者支出和创新治疗方法的采用方面处于领先地位。

FPNV定位矩阵

FPNV 定位矩阵对于评估皮肤癌诊断和治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对皮肤癌诊断和治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.皮肤癌诊断及治疗药物市场规模及预测如何？

2.皮肤癌诊断和治疗市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3.皮肤癌诊断和治疗药物市场的技术趋势和法规结构是什么？

4.皮肤癌诊断及治疗药物市场主要厂商的市场占有率是多少？

5.进入皮肤癌诊断/治疗药物市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球皮肤癌发生率和认识不断提高
      • 加强政府对皮肤癌的早期发现和治疗的努力
      • 皮肤癌诊断和治疗的开发平臺快速成长
    • 抑制因素
      • 各种皮肤癌治疗的高成本
    • 机会
      • 皮肤癌诊断与治疗药物研究进展
      • 新兴国家皮肤癌治疗的发展
    • 任务
      • 皮肤癌放射治疗的副作用
  • 市场区隔分析
    • 疾病类型：对恶性黑色素瘤的快速、早期诊断和治疗的需求日益增长
    • 类型：改善皮肤癌治疗方法的进展以满足不断增长的皮肤癌患者数量
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法规结构分析

第六章皮肤癌诊断与治疗药物市场：依疾病类型

  • 恶性黑色素瘤
  • 非黑色素瘤

第七章皮肤癌诊断与治疗药物市场：依类型

  • 诊断
  • 治疗药物

第八章北美和南美皮肤癌诊断和治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区皮肤癌诊断与治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲皮肤癌诊断和治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准首个人工智慧驱动的皮肤癌诊断工具
    • Sun Pharma 与 Philogen 合作在欧洲实现皮肤癌治疗的商业化
    • Insight 宣布 FDA核准Zynyz (Retifanlimab-Dlwr) 用于治疗转移性/復发性局部进行性默克尔细胞癌 (MCC)

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4342CA3266E1

[192 Pages Report] The Skin Cancer Diagnostics & Therapeutics Market size was estimated at USD 7.54 billion in 2023 and expected to reach USD 8.31 billion in 2024, at a CAGR 10.43% to reach USD 15.11 billion by 2030.

Skin cancer diagnostics involve a range of procedures and technologies designed to detect skin cancer at its earliest stages. The diagnostic process typically starts with a physical examination of the skin to identify suspicious lesions or moles. Once skin cancer is diagnosed, the therapeutic stage involves the treatment of the disease. Treatments can vary, as it depends on the type and stage of the cancer, and may include surgical procedures, including excision, Mohs surgery, and cryosurgery. Non-surgical options such as radiation therapy, chemotherapy, immunotherapy, and photodynamic therapy are also available and may be used either alone or in combination with surgical treatments. The rising incidence of skin cancer globally, increased healthcare investment and infrastructure, and growing awareness programs by governments and non-profit organizations have accentuated the need for skin cancer diagnostics and therapeutics. The introduction of personalized medicine and genomics into treatment protocols is also a potent driver. However, the high costs associated with advanced diagnostics and therapy, potential side effects and complications related to treatment, and disparities in access to healthcare services can impede the growth. Additionally, the procedural and technical difficulties associated with the diagnosis and therapy for skin cancer, coupled with a lack of skilled personnel, pose significant challenges. However, key players are exploring new areas of innovation, including the refinement of precision medicine techniques, the development of less toxic and more effective drug formulations, and exploring the potential of emerging fields such as immunotherapy and biologics to improve the efficiency and ease of skin care diagnostics and therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 7.54 billion
Estimated Year [2024] USD 8.31 billion
Forecast Year [2030] USD 15.11 billion
CAGR (%) 10.43%

Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas

Melanoma is a severe form of skin cancer originating in the cells that produce melanin, the pigment that gives skin its color. For diagnostics, methods such as dermoscopy, skin biopsies, lymph node mapping, and imaging tests are in demand, while treatments range from surgical excision and chemotherapy to targeted therapy and immunotherapy. Preference for these options varies based on the tumor's characteristics, staging, and patient health. Compared to non-melanoma skin cancers, melanoma requires more aggressive treatment and ongoing surveillance due to its high metastatic potential. The prognosis generally worsens with later-stage diagnoses. Therefore, early and accurate diagnostics are heavily emphasized. Non-melanoma skin cancers predominantly include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), which are generally less aggressive than melanoma. Although these cancers are more common, they have a significantly lower risk of spreading, and the treatment often involves local procedures such as surgical excision, cryosurgery, or topical medications for early stages. Photodynamic therapy and radiation may also be utilized. Non-melanoma treatments and diagnostics are usually less expensive and less complex than those for melanoma.

Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients

Diagnosis plays a highly critical role in the management of skin cancer, enabling early detection and thereby increasing the likelihood of successful treatment outcomes. The diagnostic segment includes various technologies and methods such as dermatoscopy, biopsy, imaging tests, and molecular diagnostics. While blood tests are not commonly used to diagnose skin cancer, they can provide valuable information about the patient's overall health and organ function, particularly in advanced cases where cancer may have spread. Dermatoscopy refers to a non-invasive diagnostic tool used to examine skin lesions. Imaging tests such as ultrasound, X-rays, computed tomography (CT) scans, positron emission tomography (PET), or magnetic resonance imaging (MRI) scans may be used to determine the spread of skin cancer to other parts of the body. When there is a suspicion of skin cancer spread, a lymph node biopsy can be performed to evaluate whether cancer cells have metastasized to the lymphatic system. A skin biopsy is the primary method used to diagnose skin cancer. It involves removing a sample of suspicious skin tissue, which is then examined under a microscope for the presence of cancer cells. The therapeutics for skin cancer range from surgical treatments to advanced systemic therapies and immunotherapies, with the choice of treatment usually dependent on the stage and type of skin cancer. Chemotherapy remains a potent systemic treatment modality for various stages of skin cancer, particularly for metastatic or advanced disease. It involves the use of anti-cancer drugs that are administered orally or intravenously to destroy rapidly dividing cancer cells. Non-invasive therapies have gained traction as they offer significant advantages by targeting cancer cells while minimizing damage to surrounding healthy tissue. These therapies include topical treatments, radiotherapy, or photodynamic therapy. Surgical procedures range from minimally invasive techniques such as cryosurgery, which involves freezing and destroying abnormal tissue, to more extensive surgeries such as Mohs surgery, which removes cancerous tissue layer by layer while preserving as much healthy tissue as possible.

Regional Insights

The Americas region, particularly the U.S. and Canada, harbors a sophisticated healthcare system with substantial investments in skin cancer research and diagnostics. Patient behavior is driven by high awareness levels and access to advanced therapies. Public and private entities show commitment through funding and initiatives to reduce the incidence and death rates associated with skin cancer. There is a high number of patents in the field, showcasing significant innovation in diagnostic tools such as mole mapping technologies, AI-driven image analysis, and therapeutic approaches, including targeted therapies and immunotherapies. The European Union shows substantial heterogeneity in the prevalence of skin cancer and healthcare access across member states. Investments in skin cancer research and healthcare infrastructures vary, but there is a concerted effort, showcased through initiatives such as the EU's Horizon 2020 program, to harmonize and advance the fight against skin cancer. In the APAC region, rising government support for improving the healthcare infrastructure and increasing insurance penetration is translating into a greater need for skin cancer care. Countries with advanced healthcare systems, such as Japan and Australia, lead in patient expenditure and adoption of innovative therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Skin Cancer Diagnostics & Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Skin Cancer Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Skin Cancer Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AB Science, Abbott Laboratories, Agilent Technologies, Inc., Almirall, S.A., Amgen, Inc., AMLo Biosciences Ltd., AstraZeneca PLC, bioMerieux SA, Bristol-Myers Squibb Company, Castle Biosciences, Inc., Daiichi Sankyo Company, Limited, DAMAE Medical, DermTech, Inc. by Bausch Health Companies Inc., Elekta AB, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., NeraCare GmbH, Novartis AG, Pfizer Inc., QIAGEN N.V., Sanofi S.A., Sirnaomics, Inc., SkylineDx BV, Sun Pharmaceutical Industries Ltd., and Veriskin Inc..

Market Segmentation & Coverage

This research report categorizes the Skin Cancer Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Melanoma
    • Non-melanoma
  • Type
    • Diagnosis
      • Blood Tests
      • Dermatoscopy
      • Imaging Tests
      • Lymph Node Biopsy
      • Skin Biopsy
    • Therapeutics
      • Chemotherapy
      • Non-invasive Therapy
      • Surgery
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Skin Cancer Diagnostics & Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Skin Cancer Diagnostics & Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Skin Cancer Diagnostics & Therapeutics Market?

4. What is the market share of the leading vendors in the Skin Cancer Diagnostics & Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Skin Cancer Diagnostics & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing Incidences and Rising Awareness of Skin Cancer Globally
      • 5.1.1.2. Rising Government Initiatives for Early Detection and Skin Cancer Treatment
      • 5.1.1.3. Proliferation in Research and Development Pipelines for Skin Cancer Diagnostics and Therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost Associated With the Various Skin Cancer Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Skin Cancer Diagnostics & Therapeutics
      • 5.1.3.2. Developments of Skin Cancer Care in Emerging Nations
    • 5.1.4. Challenges
      • 5.1.4.1. Side Effects of Radiation Therapy for Skin Cancer
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Growing need to ensure quick and early diagnosis and treatment of melanomas
    • 5.2.2. Type: Advancements to improve therapeutics for skin cancer to cater to the rising incidences of skin cancer patients
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework Analysis

6. Skin Cancer Diagnostics & Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Melanoma
  • 6.3. Non-melanoma

7. Skin Cancer Diagnostics & Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Therapeutics

8. Americas Skin Cancer Diagnostics & Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Skin Cancer Diagnostics & Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Skin Cancer Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
    • 11.3.2. Sun Pharma, Philogen Collaborate to Commercialise Skin Cancer Drug in Europe
    • 11.3.3. Incyte Announces FDA Approval Of Zynyz (Retifanlimab-Dlwr) For Treatment Of Metastatic/Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-MELANOMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DERMATOSCOPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LYMPH NODE BIOPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY NON-INVASIVE THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR SKIN CANCER DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024-2030 (USD MILLION)
  • TABLE 297. QATA